Docetaxel versus abiraterone for metastatic hormone-sensitive prostate cancer with focus on efficacy of sequential therapy.
Yanagisawa T, Hata K, Narita S, Hatakeyama S, Mori K, Yata Y, Sano T, Otsuka T, Hara S, Miyajima K, Enei Y, Fukuokaya W, Nakazono M, Matsukawa A, Miki J, Habuchi T, Ohyama C, Shariat SF, Kimura T.
Yanagisawa T, et al.
Prostate. 2023 May;83(6):563-571. doi: 10.1002/pros.24488. Epub 2023 Jan 20.
Prostate. 2023.
PMID: 36661102